Which Mounjaro (tirzepatide) diabetes trials led to approval, and what did they test?
Mounjaro (tirzepatide) was evaluated in large, randomized clinical programs for type 2 diabetes (T2D), testing both dose levels and different study designs (placebo- and active-comparator controlled). The key diabetes trials included SURPASS and, for longer-term cardiovascular outcomes, SURPASS-CVOT.
What were the main SURPASS trials in type 2 diabetes?
Across the SURPASS program, tirzepatide was studied in adults with T2D comparing different tirzepatide doses against placebo and/or active diabetes therapies, with outcomes focused on glycemic control (especially HbA1c reduction) and weight change.
- SURPASS 1: Compared tirzepatide with placebo in people with T2D.
- SURPASS 2: Compared tirzepatide doses with semaglutide (an active GLP-1 receptor agonist comparator).
- SURPASS 3: Compared tirzepatide doses with insulin degludec (a basal insulin comparator).
- SURPASS 4: Compared tirzepatide doses with insulin glargine (another basal insulin comparator).
- SURPASS 5: Compared tirzepatide with semaglutide 1 mg.
- SURPASS 6: Compared tirzepatide with additional active-comparator and add-on strategies depending on background therapy.
(Each SURPASS study evaluated change in HbA1c and other diabetes-relevant endpoints; dosing schedules and inclusion criteria varied by trial.)
How did the trials measure success (HbA1c and weight)?
In the diabetes trials, the primary endpoint was typically change in HbA1c from baseline, along with secondary outcomes that commonly included:
- proportion of participants reaching HbA1c targets (e.g., below common thresholds used in T2D care),
- body weight change,
- and a range of safety outcomes.
Across the program, tirzepatide generally produced greater HbA1c reductions and weight loss than comparators such as placebo, semaglutide, and basal insulin in the respective studies.
What happened in SURPASS-CVOT (cardiovascular outcomes)?
SURPASS-CVOT tested whether tirzepatide could reduce major cardiovascular events in people with T2D at high cardiovascular risk or with established disease. This study focuses on time-to-event cardiovascular outcomes rather than only glucose and weight endpoints.
What side effects came up in the diabetes trials?
Across the Mounjaro diabetes studies, the safety profile was consistent with GLP-1–based therapies, with the most common concerns typically being gastrointestinal (for example, nausea, vomiting, diarrhea, and constipation). Hypoglycemia risk depends on background therapy, especially if used with insulin or insulin secretagogues.
How are these trials different from studies in obesity-only populations?
The diabetes trials are designed around T2D populations and endpoints like HbA1c and diabetic safety outcomes. Studies in people without diabetes (often reported under different brand/indication programs) use related but not identical endpoints (commonly focused on weight loss).
If you tell me whether you mean “what studies were used for diabetes approval” or “which specific SURPASS trial matches my situation” (for example, already on insulin vs. not on insulin), I can narrow to the most relevant trial and outcomes.
Sources
I don’t have the provided source document(s) needed to cite specific Mounjaro trial publications or results. If you share the material you want me to use (or allow me to browse DrugPatentWatch.com and the trial registry/papers you prefer), I can produce a fully sourced, claim-by-claim answer with links.